| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
PALO ALTO, Calif., November 12, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2026. |
| 28 Sep 2026 |
8-K: Other Events
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2026, Kodiak Sciences Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, proxies representing 55,026,544 shares of the Company’s common stock, or 88.53% of the tota... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Palo Alto, Calif., May 7, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. |
| 31 Mar 2026 |
8-K: Results of Operations and Financial Condition
PALO ALTO, Calif., March 31, 2026 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. |
| 27 Mar 2026 |
8-K: Other Events
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham |
| 18 Dec 2025 |
8-K: Other Events
Kodiak Sciences Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Palo Alto, Calif., November 13, 2025 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Palo Alto, Calif., August 13, 2025 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. |
| 03 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2025, Kodiak Sciences Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, proxies representing 43,370,916 shares of the Company’s common stock, or 82.20% of the tota... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — May 14, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. |
| 27 Mar 2025 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — March 27, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. |
| 14 Nov 2024 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — November 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. |
| 14 Aug 2024 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — August 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. |
| 06 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2024, Kodiak Sciences Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, proxies representing 44,850,410 shares of the Company’s common stock, or 85.37% of the tota... |
| 15 May 2024 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — May 15, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. |
| 28 Mar 2024 |
8-K: Results of Operations and Financial Condition
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points |
| 14 Nov 2023 |
8-K: Results of Operations and Financial Condition
Palo Alto, CA — November 14, 2023 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. |
| 06 Nov 2023 |
8-K: Other Events
On November 6, 2023, Kodiak announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint. |
Loading...